Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Latest filing alerts

Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.

8:57 AM ET 8-K
M&A Deal Bumble Inc. BMBL

Bumble Signs $1.3B M&A Deal with Ithaca Holdings

Bumble Inc. has entered into a definitive agreement to be acquired by Ithaca Holdings in an all-cash transaction valuing the company at $1.3 billion. Under the terms of the deal, Class A shareholders will receive $6.05 per share, representing a 138% premium to the unaffected closing price. Upon completion, Bumble will become a privately-held company and Ithaca Co-CEOs Ravi Gupta and John Hegeman will lead the company alongside founder Whitney Wolfe Herd.

Value
$1.3B
Counterparty
Ithaca Holdings
8:53 AM ET 8-K
Leadership Change Danaher Corp DHR

Danaher Leadership Change

Danaher Corporation increased its Board of Directors to thirteen members and appointed Daniel L. Comas and Robert M. Hershberg as new directors, effective October 9, 2026. Mr. Comas is the company's former CFO, and Dr. Hershberg is the former CEO of HilleVax, Inc. Both will serve until the next annual meeting and participate in the standard non-employee director compensation program.

8:52 AM ET
Earnings Call Ondas Inc. ONDS ▶ Call

Ondas Earnings Call: Key Takeaways

Ondas is scaling rapidly through an integrated 'One Ondas' platform, raising 2026 revenue guidance significantly while leveraging a massive $757 million backlog and $11 billion pipeline.

8:48 AM ET Form 4
Insider Selling Ciena Corp CIEN

Ciena President & CEO Gary B. Smith Sells $1.09M of Stock

Gary B. Smith, President & CEO, sold 2,952 shares of Ciena Corp at $369.66 a share, worth $1.09M in total on Oct 1, 2026. Shares held after the trade: 228,407 (-1.3%).

Value
$1.09M
Shares
2,952
Price
$369.66
Role
President & CEO
Holding change
-1.3%
Trade date
Oct 1, 2026
8:47 AM ET 8-K
Business Update DeFi Development Corp. DFDV

DeFi Development Business Update

DeFi Development Corp. reported that its treasury holdings of SOL and SOL equivalents grew by 22,070 tokens over a one-week period, reaching a total of 2,586,282 SOL. The company highlighted that its SOL holdings have increased by 12% since August 12, 2026, and noted that its CHAD preferred stock reached record highs despite broader crypto market volatility.

Term
October 5, 2026 through October 9, 2026
8:47 AM ET 8-K
M&A Deal Workday, Inc. WDAY

Workday M&A Deal with ConductorOne, Inc.

Workday has entered into a definitive agreement to acquire C1.ai, a leading agentic identity platform for people and AI agents. The acquisition aims to integrate identity governance directly into Workday's core platform to manage real-time access for humans and autonomous agents across enterprise systems. The transaction is subject to customary closing conditions.

Counterparty
ConductorOne, Inc. (C1.ai)
8:45 AM ET 8-K
Business Update Bitmine Immersion Technologies, Inc. BMNR

Bitmine Immersion Technologies Business Update

Bitmine Immersion Technologies provided an operational update disclosing total crypto, cash, and marketable securities holdings of $16.2 billion. The company's holdings include 6.03 million ETH tokens, representing 4.9% of the total ETH supply, and 214 Bitcoin, alongside significant stakes in Beast Industries and Eightco Holdings.

8:42 AM ET 8-K
Business Update Phio Pharmaceuticals Corp. PHIO

Phio Pharmaceuticals Business Update

Phio Pharmaceuticals successfully completed its first commercial-scale cGMP batch of PH-762 drug substance, a key manufacturing milestone. This achievement validates the company's supply chain readiness and supports the planned initiation of a Phase 2b clinical trial in the first quarter of 2027.

8:39 AM ET 8-K
Partnership Ondas Inc. ONDS

Ondas Partnership with Palantir

Ondas Inc. and Palantir have launched Regna AI, a new standalone company and strategic partnership focused on providing sovereign AI solutions for defense and government sectors. Regna AI will utilize Palantir's AIP platform and Ondas' expertise in autonomous systems to deploy fine-tuned open-weight models that allow governments to maintain control over their mission data and AI models.

Counterparty
Palantir
8:36 AM ET 8-K
Clinical Trial Data CervoMed Inc. CRVO

CervoMed Clinical Trial Data

CervoMed announced positive initial 12-week biomarker data from its Phase 2a clinical trial of neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA). The data showed a mean reduction in plasma neurofilament light chain (NfL) levels, a key marker of neurodegeneration, which contrasts with the increases typically seen in the natural history of the disease.

8:36 AM ET 8-K
Regulatory Approval SAB Biotherapeutics, Inc. SABS

SAB Biotherapeutics Regulatory Approval

SAB Biotherapeutics announced that the FDA has granted Fast Track designation to SAB-142, a fully human anti-thymocyte immunoglobulin being developed for Stage 3 type 1 diabetes. The designation is intended to expedite the development and review of the immunotherapy, which is currently in a Phase 2b clinical trial. Topline data from the SAFEGUARD study is anticipated in the second half of 2027.

8:35 AM ET 8-K
Leadership Change MetaVia Inc. MTVA

MetaVia Leadership Change

MetaVia Inc. appointed Sarah Kaplan Browne, M.D. as Chief Medical Officer, effective October 12, 2026. Dr. Browne brings over 20 years of experience in clinical development and regulatory science, specifically in liver and metabolic diseases like MASH. She will lead the clinical strategy for the company's cardiometabolic pipeline, including DA-1726 and vanoglipel.

8:33 AM ET 8-K
Clinical Trial Data First Tracks Biotherapeutics, Inc. TRAX

First Tracks Biotherapeutics Clinical Trial Data

First Tracks Biotherapeutics announced positive topline data from the first Phase 1b cohort of its drug candidate ANB033 for the treatment of Celiac Disease. The company also updated its corporate investor presentation to reflect these clinical developments.

8:31 AM ET 8-K
Business Update Runway Growth Finance Corp. RWAY

Runway Growth Finance Business Update

Runway Growth Finance Corp. provided a portfolio update for the quarter ended September 30, 2026, reporting $8.5 million in follow-on fundings across four existing portfolio companies. The company also experienced significant liquidity events totaling $139.4 million, driven by full repayments from 3PL Central, Route 92 Medical, Onward Medical, and Shepherd Intermediate.

Term
Q3 2026
8:31 AM ET 8-K
Business Update California Resources Corp CRC

California Resources Business Update

California Resources Corp provided preliminary Q3 2026 operational data, reporting realized oil prices of $83.42 per barrel before derivative settlements and $72.46 after settlements. The company also estimated a $134 million loss from net settlement of commodity derivatives for the quarter. Management noted that current oil price realizations relative to Brent are not considered a long-term run rate and expects improvements from ongoing commercial and logistics actions.

Term
Q3 2026
8:31 AM ET 8-K
Investor Meeting Advasa Holdings, Inc. ADBT

Advasa Holdings Investor Meeting

Advasa Holdings announced its five-year medium-term operating goals through March 2031, targeting a significant scale-up in financial performance. The company aims to grow consolidated revenue from $18.99 million in fiscal 2027 to $632.91 million by fiscal 2031, with corresponding operating income targets rising to $189.87 million.

Term
5 years
8:30 AM ET 8-K
M&A Deal Horizon Space Acquisition I Corp. HSPOF

Horizon Space Acquisition I Signs $2B M&A Deal with ArcheNova Biotech Corp.

Horizon Space Acquisition I Corp. (HSPO), a SPAC, has entered into a definitive business combination agreement with clinical-stage biopharmaceutical company ArcheNova Biotech Corp. The transaction values ArcheNova at an implied enterprise value of $2.0 billion. Upon closing, the combined entity, ArcheNova Technology Co., Ltd, is expected to list on the Nasdaq Stock Market.

Value
$2B
Counterparty
ArcheNova Biotech Corp.
8:30 AM ET 8-K
Nasdaq/NYSE Compliance Notice Eightco Holdings Inc. ORBS

Eightco Holdings Nasdaq/NYSE Compliance Notice

Eightco Holdings Inc. has regained compliance with Nasdaq's minimum bid price requirement after its common stock closed at or above $1.00 per share for 10 consecutive business days. The company had previously received a deficiency notice on August 5, 2026, and Nasdaq has now officially closed the matter.

Counterparty
The Nasdaq Stock Market LLC
8:30 AM ET 8-K
Nasdaq/NYSE Compliance Notice Newton Golf Company, Inc. NWTG

Newton Golf Company Nasdaq/NYSE Compliance Notice

Newton Golf Company received a Staff Determination letter from Nasdaq on October 6, 2026, notifying the company that it failed to regain compliance with the $2.5 million minimum stockholders’ equity requirement. As a result, the company's common stock faces suspension and delisting unless it successfully appeals the decision. The company intends to request a hearing before a Nasdaq Hearings Panel to stay the suspension and seek continued listing.

Counterparty
The Nasdaq Stock Market LLC
8:30 AM ET Form 4
Insider Buying Saratoga Investment Corp. SAR

Saratoga Investment CEO and Director Christian L. Oberbeck Buys $446K of Stock

Christian L. Oberbeck, CEO and Director, bought 30,000 shares of Saratoga Investment Corp. at $14.83 to $14.89 a share (average $14.86) in 2 transactions, worth $446K in total between Oct 8, 2026 and Oct 9, 2026. Shares held after the trade: 30,000 (+100.0%).

Value
$446K
Shares
30,000
Average price
$14.86
Role
CEO and Director
Holding change
+100.0%
Trade date
Oct 8, 2026 to Oct 9, 2026
8:28 AM ET Form 4
Insider Buying Borr Drilling Ltd BORR

Borr Drilling Insider Tor Olav Troim Buys $11.8M of Stock

Tor Olav Troim bought 2,500,000 shares of Borr Drilling Ltd at $4.74 a share, worth $11.8M in total on Oct 9, 2026. Shares held after the trade: 37,285,941 (+7.2%).

Value
$11.8M
Shares
2,500,000
Price
$4.74
Holding change
+7.2%
Trade date
Oct 9, 2026
8:25 AM ET 8-K
Clinical Trial Data iBio, Inc. IBIO

iBio Clinical Trial Data

iBio released preclinical body-composition data from an eight-week obese non-human primate (NHP) study of its Activin E antibody candidate, IBIO-610. The study demonstrated that combining IBIO-610 with semaglutide resulted in 93% of weight loss coming from fat compared to 77% for semaglutide alone, suggesting significant muscle preservation potential. The company plans to initiate first-in-human clinical trials in the first half of 2027.

8:24 AM ET 8-K
Loan & Debt Accelevation Holdings Corp. ACCV

Accelevation Holdings $650M Debt Financing with Bank of America, N.A.

Accelevation Holdings Corp. entered into a new $650 million senior secured credit agreement consisting of a $250 million term loan and a $400 million revolving credit facility. The new facilities, which mature in October 2031, were used to repay existing debt and provide more cost-efficient capital following the company's IPO. The agreement includes financial covenants regarding net leverage and fixed charge coverage ratios starting in 2027.

Value
$650M
Counterparty
Bank of America, N.A.
Term
5 years
8:21 AM ET 8-K
M&A Deal Skydance Corp SKYD

Skydance M&A Deal with Warner Bros. Discovery, Inc.

Skydance Corporation (formerly Paramount Skydance Corporation) completed its acquisition of Warner Bros. Discovery, Inc. (WBD) on October 6, 2026. In connection with the closing, the company is executing exchange and tender offers for WBD's outstanding senior notes and distributed warrants to its Class B stockholders as a dividend.

Counterparty
Warner Bros. Discovery, Inc.
8:13 AM ET 8-K
Financial Results Johnson & Johnson JNJ

Johnson & Johnson Financial Results

Johnson & Johnson reported Q3 2026 sales growth of 5.9% to $25.4 billion, driven by strong performance in its Innovative Medicine and MedTech segments. The company raised its full-year 2026 guidance for both sales and adjusted EPS, despite a GAAP earnings impact from a one-time special charge related to talc litigation and recent M&A activity.

Term
Q3 2026

“Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio.”

Joaquin Duato, Chairman and Chief Executive Officer

“This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade.”

Joaquin Duato, Chairman and Chief Executive Officer
8:13 AM ET 8-K
Stock Buyback Sunrise Realty Trust, Inc. SUNS

Sunrise Realty Trust Announces $20M Stock Buyback

Sunrise Realty Trust's Board of Directors authorized a $20.0 million common stock repurchase program effective upon the closing of its merger with Southern Realty Trust Inc. The company intends to repurchase at least $10.0 million of its shares as soon as practicable following the merger's completion, with the remaining $10.0 million subject to specific pricing parameters.

Value
$20M
Term
through Dec 31, 2027
8:11 AM ET Form 4
Insider Buying Pedevco Corp PED

Pedevco 10% Owner Simon G. Kukes Buys $1.91M of Stock

Simon G. Kukes, 10% Owner, bought 147,070 shares of Pedevco Corp at $13.00 a share, worth $1.91M in total on Oct 8, 2026. Shares held after the trade: 4,137,543 (+3.7%).

Value
$1.91M
Shares
147,070
Price
$13.00
Role
10% Owner
Holding change
+3.7%
Trade date
Oct 8, 2026
8:11 AM ET 8-K
Loan & Debt Cipher Digital Inc. CIFR

Cipher Digital $850M Debt Financing

Cipher Digital Inc. announced a private offering of $850 million in convertible senior notes due 2032, with an additional $150 million overallotment option for purchasers. Concurrently, the company intends to exchange a portion of its existing 1.75% Convertible Senior Notes due 2030 for shares of common stock. The proceeds are intended for general corporate purposes and to manage existing debt obligations.

Value
$850M
Term
2032
8:11 AM ET 8-K
Business Update Oncolytics Biotech Inc ONCY

Oncolytics Biotech Business Update

Oncolytics Biotech provided an update on its intellectual property strategy, including the issuance of new method of use patents for pelareorep in several countries and plans for a 'next generation' composition of matter patent. The company aims to extend its patent protection into the late 2040s, building on existing manufacturing protection that currently runs through 2044.

8:09 AM ET 8-K
Clinical Trial Data Mirum Pharmaceuticals, Inc. MIRM

Mirum Pharmaceuticals Clinical Trial Data

Mirum Pharmaceuticals announced positive topline results from its Phase 3 EXPAND study of LIVMARLI (maralixibat) for ultra-rare cholestatic liver diseases, including biliary atresia. The study met its primary endpoint for pruritus improvement and all five secondary endpoints with statistical significance. The company plans to submit a supplemental New Drug Application (sNDA) to the FDA in the first half of 2027 based on these results.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.